The effect of nipradilol on hemodynamics during exercise in angina pectoris with old myocardial infarction.

Saito, Toshihiro; Sekiya, Takaomi; Yamazaki, Yasuharu; Makita, Kuninobu; Udaka, Yoshio; Inagaki, Yoshiaki

doi:10.3999/jscpt.17.465

Cited by 2 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each patient met all of the criteria for coronary artery disease and silent myocardial ischemia as detailed in a related study9 and as follows: (1) diagnosed coronary artery disease; criteria used for diagnoses were (a) angiographically documented coronary artery disease with 2 70% reduction in luminal diameter in one or more major coronary arteries, (b) documented previous myocardial infarction, or (c) a positive thallium exercise test manifested by a significant exercise-induced reversible defect; (2) stable symptoms for at least 2 months; (3) positive electrocardiogram (ECG) in exercise treadmill test and no required antianginal medication (except sublingual nitroglycerin) for 2 2-3 days prior to the test, and the ability to complete stage 2 2 of the Bruce protocol and terminated at stage S 4 because of positive ischemic ECG changes (ST-segment depression 80 ms after J points, 2 2 mm) with symptoms; (4) 2 1 episodes of asymptomatic ischemia during a 24-h screening ambulatory ECG recorded within 1 month prior to entering this study. None of the subjects had suffered a myocardial infarction within 3 months or had been subjected to coronary revascularization procedures within 6 months prior to the start of the present study, nor had any suffered from moderate to severe systemic hypertension (2 160/90 mmHg) or diabetes me'llitus.…”

Section: Methods Study Populationmentioning

confidence: 99%

Effect of nipradilol on silent myocardial ischemia, plasma beta‐endorphin, and bradykinin in chronic stable angina

Takase

Kurita

Uehata

et al. 1996

Clinical Cardiology

View full text Add to dashboard Cite

summaryHypothesis: This study was undertaken to investigate the effect of nipradilol on the total ischemic burden and on plasma levels of betaendorphin and bradykinin.Mrfh0d.s: Sixteen patients with chronic stable angina were subjected to exercise treadmill testing and 24-h ambulatory electrocardiogram (ECG).Results: Niprddilol significantly decreased both mean heart rate and mean pressure rate product at submaximal and maximal exercise. It significantly improved exercise-induced maximal ST-segment depression from -2.7 k 0.5 mm to -1.3 k 0.6 nun (~0 . 0 5 ) and reduced the number of leads with significant ST-segment depression (4.0 +. 1.2 vs. 2.0 5 1.8, p4.05). Silent ischemic episodes recorded in 24-h ambulatory ECG were significantly decreased by nipradilol administration, concomitantly with a decrement of mean hem rate and observed maximal heart rate. Patients with exercise-induced dent myocardial ischemia showed significantly increased plasma levels of beta-endorphin during both the placebo and nipradilol phases of the study. However, during the nipradilol phase, bradykinin did not change significantly at rest and at peak exercise. Conclusion: Nipradilol effectively controls exercise-induced myocardial ischemia ahd silent myocardial ischemic episodes, and does not influence the response of plasma levels of betaendorphin to exercise stress testing in patients with exercise-induced silent myocardial ischemia.

show abstract

Section: Methods Study Populationmentioning

confidence: 99%

Effect of nipradilol on silent myocardial ischemia, plasma beta‐endorphin, and bradykinin in chronic stable angina

Takase

Kurita

Uehata

et al. 1996

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…Nipradilol is a potent non‐selective β‐adrenoceptor blocking agent with nitrovasodilating properties 1–3 and, therefore, has been used for the treatment of essential hypertension 4 and angina pectoris 5,6 . The clinical use of an agent such as nipradilol, which possesses both β‐adrenoceptor blocking and vasodilator activity, 7 is considered to be an attractive approach because the β‐adrenoceptor antagonism of nipradilol can cooperate with its vasodilator action for therapeutic efficacy.…”

Section: Introductionmentioning

confidence: 99%

“…Nipradilol is a potent non-selective ␤-adrenoceptor blocking agent with nitrovasodilating properties [1][2][3] and, therefore, has been used for the treatment of essential hypertension 4 and angina pectoris. 5,6 The clinical use of an agent such as nipradilol, which possesses both ␤-adrenoceptor blocking and vasodilator activity, 7 is considered to be an attractive approach because the ␤-adrenoceptor antagonism of nipradilol can cooperate with its vasodilator action for therapeutic efficacy. Namely, ␤-adrenoceptor antagonists can block the reflex tachycardia that is caused by the vasodilating effect of the nitroxy group, while the nitroxy group can alleviate the increase in coronary vascular resistance associated with ␤-adrenoceptor blockade.…”

Section: Introductionmentioning

confidence: 99%

β‐Adrenoceptor Blocking Activities Of Nipradilol And Its Optical Isomers In Pig Coronary Artery

Itomine

Matsuzaki

Sakanashi

et al. 2001

Clin Exp Pharma Physio

View full text Add to dashboard Cite

1. beta-Adrenoceptor blocking activities of nipradilol, its four optical isomers (RR, RS, SR, SS) and denitro nipradilol were evaluated using pig isolated coronary arteries. 2. (-)-Isoprenaline produced concentration-dependent relaxations of the arteries, which were antagonized by nipradilol, its four optical isomers or denitro nipradilol under KCl-induced contracture. 3. The order of pA2 values for beta-adrenoceptor blocking activities was SR > nipradilol > SS > or = denitro nipradilol > RR > RS. 4. The nitroxy group in nipradilol appears to enhance its beta-adrenoceptor blocking activity, because the beta-adrenoceptor blocking activity of nipradilol was more potent than that of denitro nipradilol. 5. Isomers that have the S configuration (SR, SS) at the 2' position (having a hydroxyl group) in the aryloxypropanolamine showed more potent beta-adrenoceptor blocking activity than isomers that have the R configuration (RR, RS). 6. Isomers that have the R configuration (SR, RR) at the 3 position (having a nitroxy group) in the benzopyran ring showed more potent beta-adrenoceptor blocking activity than those with the S configuration (SS, RS). 7. It is suggested that the difference in configuration of the chemical structure of nipradilol may result in variations of binding affinity for the beta-adrenoceptor.

show abstract

The effect of nipradilol on hemodynamics during exercise in angina pectoris with old myocardial infarction.

Cited by 2 publications

References 6 publications

Effect of nipradilol on silent myocardial ischemia, plasma beta‐endorphin, and bradykinin in chronic stable angina

Effect of nipradilol on silent myocardial ischemia, plasma beta‐endorphin, and bradykinin in chronic stable angina

β‐Adrenoceptor Blocking Activities Of Nipradilol And Its Optical Isomers In Pig Coronary Artery

Contact Info

Product

Resources

About